As a percentage of per capita income in each country, the prices are much closer: US 158%, Germany 165%, and UK 153%. My guess though is that Britain's figure is lower overall because it is willing to ration the provision of health services to its citizens.
"If those pricing talks don't work--and Merck $MRK), at least, has said it's not interested in a price war--then insurers' only recourse will be to limit volume, Reimbursement Intelligence's John Whang told the news service. That presumably means strict prior authorization policies to direct expensive hep C drugs only to the sickest patients."
That also sounds like a lot of expensive law suits directed against insurance companies by patients who believe they are entitled to SOC drugs.
Market Data 
Markets 
AI
